XenoPort Sinks as Spasticity Drug For MS Fails in Trial
This article is for subscribers only.
XenoPort Inc., the maker of the drug Horizant for Restless Legs Syndrome, sank the most in almost three years after an experimental medicine failed to meet goals of a late-stage clinical trial.
XenoPort dropped 15 percent to $5.72 at the close in New York, the biggest single-day decline since July 2010. The shares of the Santa Clara, California-based company have declined 26 percent this year.